Non‐invasive prenatal diagnosis of single gene disorders by paternal mutation exclusion: 3 years of clinical experience
- 20 May 2022
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 129 (11) , 1879-1886
Abstract
Objectives: Cell‐free fetal DNA (cffDNA) analysis is performed routinely for aneuploidy screening, RhD genotyping or sex determination. Although applications to single gene disorders (SGD) are being rapidly developed worldwide, only a few laboratories offer cffDNA testing routinely as a diagnosis service for this indication. In a previous report, we described a standardised protocol for non‐invasive exclusion of paternal variant in SGD. Three years later, we now report our clinical experience with the protocol.Design: Descriptive study.Setting: Multi‐centre French.Population: Indications for referral included pregnancies at risk of 25% or 50% of paternally inherited SGD, and pregnancies associated with an increased risk of SGD due to a de novo variant, either from strongly suggestive ultrasound findings or from a possible parental germinal mosaicism in the context of a previously affected child.Methods: Non‐invasive prenatal diagnosis was performed using custom assays for droplet digital PCR. Feasibility, diagnostic performance and turn‐around time were evaluated.Results: Mean time for a new assay design and validation was evaluated at 14 days, and mean result reporting time was 6 days. All referred pathogenic variants could be targeted except one located in a complex genomic region. A result was obtained for every 198 referrals except two.Conclusion: This service was successfully implemented as a routine laboratory practice. It has been widely adopted by French clinicians and patients for paternal variant exclusion in various disorders.Tweetable A robust approach to non‐invasive prenatal exclusion of paternal pathogenic variant in a diagnosis setting.Keywords
Funding Information
- French Muscular Dystrophy Association
- Association Vaincre la Mucoviscidose
- Agence de la Biomédecine
This publication has 35 references indexed in Scilit:
- Procedure‐related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta‐analysisUltrasound in Obstetrics & Gynecology, 2014
- Noninvasive Prenatal Diagnosis of Congenital Adrenal Hyperplasia Using Cell-Free Fetal DNA in Maternal PlasmaThe Journal of Clinical Endocrinology & Metabolism, 2014
- Gestational age and maternal weight effects on fetal cell‐free DNA in maternal plasmaPrenatal Diagnosis, 2013
- Noninvasive Fetal Sex Determination Using Cell-Free Fetal DNAJAMA, 2011
- Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the FetusScience Translational Medicine, 2010
- Update on Procedure-Related Risks for Prenatal Diagnosis TechniquesFetal Diagnosis and Therapy, 2009
- Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasmaProceedings of the National Academy of Sciences, 2008
- Microfluidics Digital PCR Reveals a Higher than Expected Fraction of Fetal DNA in Maternal PlasmaClinical Chemistry, 2008
- Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility studyBMJ, 2008
- RHD Genotyping from Maternal Plasma: Guidelines and Technical Challenges2008